<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Childhood absence epilepsy
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Childhood absence epilepsy
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Childhood absence epilepsy
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Christian M Korff, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Douglas R Nordli, Jr, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John F Dashe, MD, PhD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 16, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H383785423">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Childhood absence epilepsy (CAE) is a common generalized epilepsy syndrome with a presumed polygenic cause, characterized by typical absence seizures appearing in otherwise healthy school-aged children. CAE is one of the most common forms of pediatric epilepsy.
        </p>
        <p>
         The clinical features, diagnosis, treatment, and prognosis of CAE are discussed here. Other epilepsy syndromes with an onset in childhood are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6199.html" rel="external">
          "Seizures and epilepsy in children: Classification, etiology, and clinical features"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6162.html" rel="external">
          "Epilepsy syndromes in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/17192.html" rel="external">
          "Juvenile myoclonic epilepsy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4206893180">
         <span class="h1">
          CLASSIFICATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         CAE is classified as an epilepsy syndrome with presumed polygenic cause according to the International League Against Epilepsy (ILAE) [
         <a href="#rid1">
          1-3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14094.html" rel="external">
          "ILAE classification of seizures and epilepsy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CAE is one of the idiopathic generalized epilepsies (IGEs)
         </strong>
         – The ILAE described a broad group of genetic generalized epilepsies (GGEs) that are characterized by generalized seizure types and generalized spike-wave with a presumed genetic etiology  (
         <a class="graphic graphic_figure graphicRef141084" href="/z/d/graphic/141084.html" rel="external">
          figure 1
         </a>
         ). Contained within the GGEs is a subgroup of IGEs comprised of four syndromes [
         <a href="#rid3">
          3
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         CAE
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Juvenile absence epilepsy (JAE)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Juvenile myoclonic epilepsy (JME)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Epilepsy with generalized tonic-clonic seizures alone (GTCA)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Shared features of IGEs
         </strong>
         – The IGEs are the most common epilepsy syndromes within the GGEs and have several shared characteristics, including [
         <a href="#rid3">
          3
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A relatively good prognosis for seizure control
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Typically normal development
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Clinical overlap among CAE, JAE, and JME
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Possible evolution with age from one to another IGE syndrome
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Similar electroencephalography (EEG) findings (2.5 to 6 Hz generalized spike-wave that may activate with hyperventilation or photic stimulation)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Polygenic inheritance likely
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H383785435">
         <span class="h1">
          ETIOLOGY AND GENETICS
         </span>
         <span class="headingEndMark">
          —
         </span>
         CAE has a strong complex genetic component resulting from variation within multiple genes and their interaction with environmental factors [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14600.html" rel="external">
          "Principles of complex trait genetics"
         </a>
         .)
        </p>
        <p>
         A genetic cause of CAE has been suggested by family and twin studies, although clear single-gene defects that reliably result in a typical CAE phenotype have not yet been identified. Family studies indicate a 17 percent risk of having typical absence seizures in first-degree relatives of patients with CAE [
         <a href="#rid4">
          4
         </a>
         ], and there is a higher concordance rate for CAE in monozygotic than dizygotic pairs [
         <a href="#rid5">
          5
         </a>
         ]. However, most patients with idiopathic generalized epilepsies (IGEs) do not have a family history of epilepsy [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Susceptibility genes
         </strong>
         – Several candidate regions and genes have been identified as possible susceptibility loci in CAE. Copy number variations and microdeletions in regions such as 8q and 15q have been reported in a minority of patients with IGE syndromes, including some with CAE [
         <a href="#rid6">
          6-9
         </a>
         ]. One group performed sequencing of the 15q candidate region in 380 patients with CAE and identified heterozygous point mutations in
         <em>
          NIPA2
         </em>
         , a gene that encodes for a selective magnesium transporter, in 3 of 380 patients with CAE and in none of the 400 controls [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Most of the genes otherwise reported code for various subunits of gamma-aminobutyric acid A (GABA-A) receptors [
         <a href="#rid11">
          11-18
         </a>
         ], GABA-B receptors [
         <a href="#rid16">
          16,19
         </a>
         ], calcium channels [
         <a href="#rid16">
          16,19-24
         </a>
         ], or chloride channels [
         <a href="#rid25">
          25,26
         </a>
         ], although validation has generally been lacking and ethnic variation may contribute to the heterogeneity in findings [
         <a href="#rid17">
          17,27-30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           SLC2A1
          </em>
         </strong>
         <strong>
          gene
         </strong>
         –
         <em>
         </em>
         Another gene of interest in CAE is
         <em>
          SLC2A1
         </em>
         , which encodes the glucose transporter GLUT1. Mutations in
         <em>
          SLC2A1
         </em>
         were found in up to 10 to 12 percent of children presenting with absence epilepsy starting before four years or refractory absences [
         <a href="#rid31">
          31-35
         </a>
         ]. By contrast, no
         <em>
          SLC2A1
         </em>
         mutations were found in 84 subjects with CAE as defined by the onset of absences after four years, documented electroclinical typical absence seizures with generalized 3 to 4 Hz spike-wave and normal background EEG activity, normal neurodevelopmental examination, and normal brain imaging [
         <a href="#rid36">
          36
         </a>
         ]. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/139238.html" rel="external">
          "Overview of infantile epilepsy syndromes", section on 'Glut1 deficiency syndrome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4002033">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Studies in humans and rodent models have implicated a variety of cortical and thalamocortical circuits in the genesis of typical absence seizures [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
         Most data point to prominent involvement of deep layers of the frontal and somatosensory cortex in the generation of slow wave discharges, with rapid spread to other regions of the cortex and secondary invasion of the thalamus [
         <a href="#rid38">
          38-41
         </a>
         ]. The orbital-medial frontal and medial-lateral parietal cortices have been implicated in studies utilizing simultaneous EEG and functional magnetic resonance imaging (fMRI) during typical slow wave discharges [
         <a href="#rid42">
          42,43
         </a>
         ]. In another study, the posterior cortical regions were active at the onset of the slow wave discharge, followed by spread to other areas later in the seizure, including the thalamic medial dorsal nuclei and the thalamostriate network [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
         Animal data indicate that particular cortical and thalamic excitability and coupling conditions must occur to produce the slow wave discharges of typical absence seizures [
         <a href="#rid38">
          38
         </a>
         ]. Enhanced tonic gamma-aminobutyric acid A (GABA-A) receptor inhibition in thalamocortical neurons has been demonstrated to be necessary and sufficient for the expression of typical absence seizures in various pharmacologic and genetic mouse models [
         <a href="#rid45">
          45
         </a>
         ]. Such inhibition is due to increased extracellular GABA concentrations related to dysfunction of GABA transporter GAT1, an astrocytic transporter involved in GABA synaptic uptake [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1756084566">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         CAE is one of the most common forms of pediatric epilepsy, accounting for 12 to 18 percent of epilepsy diagnoses in school-aged children [
         <a href="#rid3">
          3,46,47
         </a>
         ].
        </p>
        <p>
         In a retrospective analysis of EEG findings of Swedish children aged 0 to 15 years, the annual incidence of "absence epilepsy" was 6.3 per 100,000 [
         <a href="#rid48">
          48
         </a>
         ]. In another report based on a questionnaire sent to patients with seizures in southwest France, the annual incidence of CAE was estimated at 8 per 100,000 [
         <a href="#rid49">
          49
         </a>
         ]. Of note, estimates of the annual incidence of CAE are derived from studies performed in primarily White populations.
        </p>
        <p>
         Unlike most epilepsy syndromes, CAE is more common in girls (60 to 75 percent of cases) than boys [
         <a href="#rid3">
          3,50,51
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3450332146">
         <span class="h1">
          CLINICAL FEATURES
         </span>
        </p>
        <p class="headingAnchor" id="H3446397465">
         <span class="h2">
          Clinical presentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         CAE is characterized by typical absence seizures occurring in otherwise healthy children. The median age of onset of CAE is six years [
         <a href="#rid52">
          52,53
         </a>
         ]. The majority of patients present between 4 and 10 years of age [
         <a href="#rid50">
          50
         </a>
         ]. Up to 20 percent of children have a history of febrile seizures and nearly half have a first- or second-degree relative with seizures [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6941749">
         <span class="h2">
          Seizure semiology
         </span>
         <span class="headingEndMark">
          —
         </span>
         The hallmark seizure type of CAE is the typical absence seizure. A minority of patients may develop generalized tonic-clonic seizures (GTCS) (see
         <a class="local">
          'Generalized tonic-clonic seizures'
         </a>
         below). Other seizure types are rare in CAE.
        </p>
        <p class="headingAnchor" id="H257870179">
         <span class="h3">
          Typical absence seizures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Typical absence seizures present as short and frequent episodes of profound impairment of consciousness, usually without loss of body tone, lasting approximately 10 seconds. Loss of body tone or incontinence can sometimes occur [
         <a href="#rid3">
          3
         </a>
         ]. They are abrupt in onset and termination and are easily provoked by hyperventilation. These usually come to the attention of parents, caregivers, or teachers after a prolonged period of observation, despite their high frequency. Typical absence seizures may occur multiple times daily, but their subtle clinical symptoms allow them to go unnoticed or misdiagnosed as inattention.
        </p>
        <p>
         The electroclinical spectrum of typical absence seizures in CAE is illustrated by two studies that reviewed a combined total of over 2000 absence seizures in more than 450 drug-naïve children with a new diagnosis of CAE [
         <a href="#rid3">
          3,52,54
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Seizure onset
         </strong>
         – Approximately half of all recorded seizures begin with an arrest in activity, which is typically complete. Less common first signs include eyelid movements, eye opening, and oral automatisms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ictal signs and symptoms
         </strong>
         – The majority of electrographic seizures (approximately 80 percent) are associated with at least one clinical sign. The three most common seizure features are pause/stare (80 to 95 percent), motor automatisms (40 to 60 percent), and eye involvement (55 percent). Approximately one-third of seizures involve 3 Hz regular eyelid movements. Motor automatisms are predominantly oral. The state of consciousness is deeply disturbed, with lack of awareness during the episode and inability to recall the event.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Seizure duration
         </strong>
         – The typical seizure duration is 4 to 20 seconds, with a median duration of 9 to 10 seconds. Approximately 25 percent of seizures last less than four seconds and approximately 10 percent are longer than 20 seconds.
        </p>
        <p>
        </p>
        <p>
         Hyperventilation is an effective trigger of typical absence seizures, provoking seizures in 90 percent of children old enough to perform the maneuver [
         <a href="#rid52">
          52
         </a>
         ]. Typical absence seizures are rarely provoked by sensory or visual stimuli, although intermittent photic stimulation may provoke a photoparoxysmal response in a minority of patients [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         The presence of high-amplitude limb myoclonias, head nods, hypotonia, or focal signs are not consistent with typical absence seizures and should raise suspicion for other types of seizures, such as atypical absence, myoclonic absence, myoclonic-atonic, or focal seizures. In addition, atypical absences should be suspected if the duration of the events exceeds the classic 10 to 20 seconds of typical absence seizures, especially if onset and termination are progressive rather than abrupt. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H488135736">
         <span class="h3">
          Generalized tonic-clonic seizures
         </span>
         <span class="headingEndMark">
          —
         </span>
         GTCS may be seen in patients with CAE, but only rarely before puberty. The presence of GTCS prior to or during the active period of typical absence seizures is considered an alert criterion that reduces confidence in the diagnosis of CAE. (See
         <a class="local">
          'Diagnosis'
         </a>
         below.)
        </p>
        <p>
         While GTCS have been reported in up to 60 percent of children in some series [
         <a href="#rid50">
          50,53
         </a>
         ], the true proportion is likely much lower when stringent diagnostic criteria for CAE are used. In two long-term follow-up studies of children with CAE, only 12 to 13 percent of children with CAE developed GTCS [
         <a href="#rid55">
          55,56
         </a>
         ]. In the larger series, the median time to development of GTCS was 4.7 years, and the median age at first GTCS was 13 years [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H383785455">
         <span class="h2">
          Behavioral and psychiatric comorbidities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Attention deficit hyperactivity disorder (ADHD), anxiety, mood disorders, and learning disorders are common comorbidities in children with CAE [
         <a href="#rid3">
          3,57-59
         </a>
         ]. Similar findings have also been reported in children with other idiopathic generalized epilepsy syndromes that are typically associated with a favorable prognosis. In these reports, cognitive, social, emotional, or psychiatric comorbidities frequently antedate the epilepsy onset and require special educational interventions [
         <a href="#rid54">
          54,57,60-64
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H310833251">
         <span class="h3">
          ADHD
         </span>
         <span class="headingEndMark">
          —
         </span>
         ADHD is a common comorbidity of CAE in many children and is not simply the result of frequent seizures [
         <a href="#rid57">
          57,65
         </a>
         ]. The pattern of deficits tends to be more inattentive than hyperactive, which can make recognition of the deficits difficult for teachers and parents or caregivers [
         <a href="#rid65">
          65-67
         </a>
         ]. Seizure duration rather than overall seizure frequency is one predictor of attentional dysfunction, but additional risk factors are not well established. In a cohort of 445 children with CAE, 36 percent of children had baseline attention deficits despite intact cognitive functioning [
         <a href="#rid67">
          67
         </a>
         ]. Another study of the same cohort found that the rate of subtle attentional difficulties was higher in the 30 percent of children who had at least one seizure longer than 20 seconds on initial EEG [
         <a href="#rid68">
          68
         </a>
         ]. However, the overall number of seizures was not associated with measures of attention or executive function. (See
         <a class="medical medical_review" href="/z/d/html/624.html" rel="external">
          "Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2043399398">
         <span class="h3">
          Cognition and learning
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children with CAE typically have intact cognition and intellect at the time of diagnosis. Formal neurocognitive testing may detect mild deficits in a variety of domains, particularly executive function [
         <a href="#rid61">
          61
         </a>
         ]. In a study that compared neuropsychologic and academic function in 94 children aged 8 to 18 years with new-onset epilepsy with 72 healthy subjects, specific difficulties in fine motor skills and executive functions were noted in children with both childhood and juvenile absence epilepsy [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
         In another study that examined behavioral, cognitive, and linguistic comorbidities in 69 children with CAE and 103 age-matched healthy subjects, children with CAE had significantly lower scores on global, verbal, and performance intellectual quotients and speech language quotients [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3122798990">
         <span class="h3">
          Anxiety and depression
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with CAE have higher rates of anxiety and depression compared with the general population [
         <a href="#rid57">
          57,69
         </a>
         ]. In a meta-analysis of five case-control studies with 231 patients with absence seizures and 281 controls, the likelihood of developing depression or anxiety was greater for patients with absence seizures compared with controls (29.0 versus 7.5 percent, odds ratio 4.93, 95% CI 2.91-8.35) [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3365918435">
         <span class="h1">
          EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The evaluation of patients with suspected absence seizures includes a history, examination, and EEG, as detailed below. Brain imaging is not necessary for the diagnosis of CAE in otherwise typical cases.
        </p>
        <p class="headingAnchor" id="H2125495426">
         <span class="h2">
          History
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical features are important to differentiate CAE from other types of epileptic and nonepileptic events. The history should focus on event description, including frequency and duration, age of onset, history of other seizure types, and developmental history; CAE typically occurs in otherwise healthy school-aged children [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p>
         Eyewitness descriptions of events from parents or teachers are critical to the diagnosis. Features that suggest absence seizures should be specifically questioned [
         <a href="#rid3">
          3,70
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Staring spells or sudden loss of facial expression
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Repetitive movements such as eye blinking, head nodding, or lip smacking
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Interruption of activity
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Events unresponsive to external stimuli
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Occurrence of events regardless of setting (eg, occurring during activity such as playing and not only in passive settings such as watching TV)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2946644908">
         <span class="h2">
          Examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most children with suspected CAE will have a normal physical and neurologic examination. The goal of the examination is to detect signs of an underlying medical or neurologic disorder other than CAE that may be the cause of the events (eg, cognitive impairment, microcephaly, or eye-movement abnormalities suggestive of glucose transporter 1 [GLUT1] deficiency syndrome). (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1909270892">
         <span class="h2">
          Hyperventilation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Absence seizures can be provoked by hyperventilation in approximately 90 percent or more of untreated patients with CAE [
         <a href="#rid52">
          52,71,72
         </a>
         ]. Hyperventilation can be performed in the clinic by asking the child to blow hard on a pinwheel, imaginary candle, or other object for three minutes [
         <a href="#rid70">
          70
         </a>
         ]. It is advisable to prepare the child by letting them know you may call out a word during the hyperventilation trial and will ask them to repeat that word back, to check for retained consciousness during a pause in breathing.
        </p>
        <p class="headingAnchor" id="H454490283">
         <span class="h2">
          Electroencephalography
         </span>
         <span class="headingEndMark">
          —
         </span>
         A routine EEG with hyperventilation is usually sufficient to record an absence seizure and obviate the need for a video-EEG. If the initial EEG is normal but the clinical suspicion for CAE is high, then a sleep-deprived or prolonged video-EEG study that includes both hyperventilation and intermittent photic stimulation (IPS) may be helpful to maximize the chance of recording an absence seizure and elucidate the diagnosis. Careful annotations of the recording regarding the response of the patient to test items are critical.
        </p>
        <p>
         Among 47 consecutive patients with newly-diagnosed CAE, diagnostic 30-minute sleep-deprived video-EEG recordings captured an average of six seizures per child; of these, 47 percent occurred with hyperventilation, 25 percent during drowsiness, 13 percent during the awake state, 9 percent during IPS, and 7 percent during sleep [
         <a href="#rid52">
          52
         </a>
         ]. At least one seizure was provoked during hyperventilation in 83 percent of children.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Interictal EEG
         </strong>
         – The interictal EEG in CAE shows normal background activity, although it is common to see occasional generalized spike-wave discharges or focal abnormalities. In a review 445 pretreatment EEGs, occipital intermittent rhythmic delta activity (OIRDA) was noted in 21 percent, focal sharp waves in 2.5 percent, and focal slowing in 0.7 percent [
         <a href="#rid68">
          68
         </a>
         ]. In another study, focal intermittent paroxysmal activity was noted in 38 percent of 29 children with CAE, consisting in most cases of frontal spike-wave or polyspike and wave discharges [
         <a href="#rid73">
          73
         </a>
         ]. IPS may provoke a photoparoxysmal response (generalized spike-wave) in up to 21 percent of patients [
         <a href="#rid3">
          3,74
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/141386.html" rel="external">
          "Photosensitive epilepsies", section on 'Photoparoxysmal response'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ictal EEG
         </strong>
         – The EEG appearance of a typical absence seizure consists of generalized 2.5 to 5.5 Hz spike-wave discharges (classically 3 Hz) with abrupt onset and termination  (
         <a class="graphic graphic_waveform graphicRef91022" href="/z/d/graphic/91022.html" rel="external">
          waveform 1
         </a>
         ) [
         <a href="#rid52">
          52
         </a>
         ]. Spike-wave discharges are often stereotyped but may begin and end with discharges that have smaller amplitudes than the main body of the ictus. Pre-ictal and postictal slowing is often present [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The morphologic characteristics of the spike-wave discharges vary across recordings. In one study, 87 percent of spike-wave discharges contained only one or two spikes per wave during the seizure; four or more spikes per wave were present in 8 percent of the 47 children when analyzed individually [
         <a href="#rid52">
          52
         </a>
         ]. In another study, single spike-wave discharges were noted in 604 of 721 discharges (84 percent), whereas polyspike wave discharges were present in only 3 percent [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The ictal EEG of atypical absences usually shows discharges of irregular generalized spike waves of lower frequency (&lt;2.5 Hz) than those observed in typical absence seizures.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In up to 50 percent of cases, the earliest ictal abnormalities are focal [
         <a href="#rid52">
          52
         </a>
         ]. This is often predominant in the frontal EEG electrodes bilaterally, a phenomenon referred to as "frontal lead-in" or "frontal absences" by some authors [
         <a href="#rid75">
          75,76
         </a>
         ]. Similar features have also been reported arising from the occipital lobes [
         <a href="#rid52">
          52
         </a>
         ]. However, an EEG with a focal "lead-in" of absence seizures is not necessarily indicative of a focal structural lesion or focal epilepsy. Brain imaging, seizure semiology, and other EEG features should be considered to determine if a process other than CAE is occurring in those patients who demonstrate seizure intractability.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H383785491">
         <span class="h2">
          Neuroimaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Brain MRI is by definition normal in patients with CAE, and structural imaging is not necessary for the diagnosis if patients have typical clinical and EEG findings.
        </p>
        <p>
         High-resolution structural imaging has been used to demonstrate subtle anatomical variation in various brain regions in patients with CAE, although the functional and clinical significance of these findings is uncertain. Reported abnormalities include decreased thalamic gray matter volume and subcallosal gyrus atrophy [
         <a href="#rid77">
          77
         </a>
         ], gray matter loss in the left orbital-frontal gyrus and bilateral temporal lobes [
         <a href="#rid78">
          78
         </a>
         ], and amygdala volume loss in CAE patients with symptoms of attention deficit hyperactivity disorder (ADHD) [
         <a href="#rid79">
          79
         </a>
         ]. Volumetric analyses of 3 Tesla MRI scans in 18 patients with CAE and 18 age-matched control subjects showed that patients with CAE had reduced bilateral frontotemporal cortical gray matter volume and increased posterior medial cortical thickness [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2767028910">
         <span class="h2">
          CSF and genetic testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         To rule out GLUT1 deficiency, lumbar puncture for cerebrospinal fluid (CSF) analysis (looking for low CSF glucose) and genetic testing (for
         <em>
          SLC2A1
         </em>
         pathogenic variants) are indicated for children with any of the following [
         <a href="#rid3">
          3
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Onset at three years of age or younger
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Microcephaly
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intellectual disability
        </p>
        <p>
        </p>
        <p>
         However, these tests are not needed in most patients. (See
         <a class="local">
          'Exclusionary criteria'
         </a>
         below and
         <a class="local">
          'Other epilepsies'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H383785497">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         CAE is diagnosed based on history, examination, and video-EEG findings along with updated diagnostic criteria as proposed by the International League Against Epilepsy (ILAE) in 2022  (
         <a class="graphic graphic_table graphicRef141085" href="/z/d/graphic/141085.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid3">
          3,50,81
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2593427627">
         <span class="h2">
          Mandatory criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         A diagnosis of CAE requires [
         <a href="#rid3">
          3
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Typical absence seizures (see
         <a class="local">
          'Typical absence seizures'
         </a>
         above)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         EEG with paroxysms of 3 Hz (range 2.5 to 4.0 Hz) generalized spike-wave discharges at the start of the absence
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2122417361">
         <span class="h2">
          Alert criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following alert criteria are absent in most patients with CAE. Alerts do not exclude the diagnosis but reduce confidence in diagnostic certainty and should prompt further investigations to rule out other conditions [
         <a href="#rid3">
          3
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Generalized tonic-clonic seizures (GTCS) prior to or during the period of frequent absence seizures
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Staring spells with typical duration greater than 30 seconds or with postictal confusion or fatigue
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Absences occurring less than daily in an untreated patient
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         EEG findings:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Consistently unilateral epileptiform discharges
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lack of hyperventilation-activated 2.5 to 4.0 Hz generalized spike-wave in an untreated patient who performs hyperventilation well for three minutes or longer
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Recording a typical staring spell without EEG correlate in a child with a history of 2.5 to 4.0 Hz generalized spike-wave
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Persistent slowing of the EEG background in the absence of sedating medication
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age at onset 2 to 3 years or 11 to 13 years
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mild intellectual disability at onset
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Potentially relevant neurologic examination and/or imaging abnormalities, excluding incidental findings
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2941329698">
         <span class="h2">
          Exclusionary criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following are exclusionary for the diagnosis of CAE [
         <a href="#rid3">
          3
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Any of the following seizure types:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prominent myoclonic seizures
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prominent eyelid myoclonia
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Myoclonic absence seizures
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Atonic seizures
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Tonic seizures
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Atypical absence seizures
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Focal impaired awareness seizures
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         EEG with diffuse background slowing
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age at onset less than 2 years or greater than 13 years
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Moderate to profound intellectual disability at onset
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cognitive stagnation or decline
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low cerebrospinal fluid (CSF) glucose and/or
         <em>
          SLC2A1
         </em>
         pathogenic variant
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H383785503">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The first step in the differential diagnosis of CAE is to identify the nature of the paroxysmal events and determine whether they are electroclinical typical absence seizures or nonepileptic staring spells. This is usually easy to do and often only requires a short video-EEG recording [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H991288124">
         <span class="h2">
          Nonepileptic disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nonepileptic staring spells can occur in normal children as well as in association with attention deficit hyperactivity disorder (ADHD), autism, and intellectual disability. Unlike typical absence seizures, staring spells can be interrupted by tactile or vocal stimulation, rarely occur during physical activity, and are never associated with automatisms or other motor signs. (See
         <a class="medical medical_review" href="/z/d/html/6155.html" rel="external">
          "Nonepileptic paroxysmal disorders in children", section on 'Nonepileptic staring spells'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2233343823">
         <span class="h2">
          Other epilepsies
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to CAE, absence seizures may be seen in other generalized epilepsy syndromes, including juvenile absence epilepsy (JAE) and juvenile myoclonic epilepsy (JME), as well as rare cases of glucose transporter 1 (GLUT1) deficiency syndrome (GLUT1DS), epilepsy with eyelid myoclonia (EEM), and epilepsy with myoclonic absences (EMA):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Juvenile absence epilepsy
         </strong>
         – JAE is a generalized epilepsy also characterized by typical absence seizures but with a later peak age of onset of 10 to 12 years. In addition to later age of onset, distinguishing features of JAE include myoclonic seizures in approximately one-fifth of patients and a higher incidence of generalized tonic-clonic seizures (GTCS), which are uncommon in CAE  (
         <a class="graphic graphic_table graphicRef141086" href="/z/d/graphic/141086.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Juvenile myoclonic epilepsy
         </strong>
         – Approximately 20 to 40 percent of patients with JME have typical absence seizures, which typically begin several years before the onset of myoclonic seizures and GTCS. Compared with CAE, the typical absence seizures that occur in JME are typically milder with less complete impairment of awareness, and the spike-wave discharges on EEG are often of slightly higher frequency (ie, 4 to 6 Hz). (See
         <a class="medical medical_review" href="/z/d/html/17192.html" rel="external">
          "Juvenile myoclonic epilepsy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          GLUT1 deficiency syndrome
         </strong>
         – In patients with early-onset absences (ie, &lt;4 years of age), GLUT1 deficiency syndrome should also be considered [
         <a href="#rid32">
          32,82
         </a>
         ]. GLUT1 deficiency is a genetic disorder characterized by impaired glucose transport across the blood-brain barrier. The diagnosis is suggested by a low cerebrospinal fluid (CSF) glucose level and can be confirmed in most cases by genetic testing for
         <em>
          SLC2A1
         </em>
         . The phenotypic spectrum includes not only early-onset absence seizures but also other forms of generalized epilepsies, developmental delay, and paroxysmal exertional dyskinesias that usually emerge during childhood or adolescence [
         <a href="#rid35">
          35,83-85
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients with GLUT1 deficiency syndrome, treatment with the ketogenic diet can result in marked clinical improvement. Other dietary interventions are also under investigation. In small pilot studies, consumption of
         <a class="drug drug_pediatric" data-topicid="128894" href="/z/d/drug information/128894.html" rel="external">
          triheptanoin
         </a>
         , a medium-chain triglyceride, has been associated with significant reduction in spike-wave burden, improvement in neuropsychologic performance, and fewer paroxysmal motor events in children with GLUT1 deficiency who are not receiving the ketogenic diet [
         <a href="#rid86">
          86,87
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6218.html" rel="external">
          "Seizures and epilepsy in children: Clinical and laboratory diagnosis", section on 'Laboratory and genetic testing in undiagnosed epilepsy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14438.html" rel="external">
          "Ketogenic dietary therapies for the treatment of epilepsy", section on 'Particularly responsive conditions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epilepsy with eyelid myoclonia
         </strong>
         – EEM is a genetic generalized epilepsy with onset in the first two decades of life, characterized by eyelid myoclonia, absence seizures, and photosensitivity [
         <a href="#rid88">
          88
         </a>
         ]. By contrast, prominent eyelid myoclonia is not seen in CAE [
         <a href="#rid89">
          89
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/141386.html" rel="external">
          "Photosensitive epilepsies", section on 'Epilepsy with eyelid myoclonia (Jeavons syndrome)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epilepsy with myoclonic absences
         </strong>
         – EMA is a genetic generalized epilepsy syndrome with daily myoclonic absence seizures as the predominant type [
         <a href="#rid89">
          89
         </a>
         ]. These seizures are associated with 3 Hz upper-limb jerks and progressive arm elevation (ratcheting up), and they typically cause the patient to bend forward during the seizure. By contrast, myoclonic jerks in CAE may occur but are subtle, low amplitude, lack rhythmicity, and are not associated with progressive arm elevation [
         <a href="#rid89">
          89
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Atypical absence seizures
         </strong>
         – Atypical absences or absences with special features are usually observed in more severe forms of epilepsy, such as Lennox-Gastaut syndrome, as well as epilepsy with eyelid myoclonia and epilepsy with myoclonic absences mentioned above [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/138854.html" rel="external">
          "Lennox-Gastaut syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H383785509">
         <span class="h1">
          TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H119731131">
         <span class="h2">
          Goals of therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Typical absence seizures are characteristically extremely frequent, occurring multiple times each day. Once they are recognized, they should be treated to improve quality of life, school performance, and social acceptance, and possibly to reduce the risk of (rarely) associated convulsive seizures. Complete seizure freedom can often be attained by pharmacologic treatment.
        </p>
        <p class="headingAnchor" id="H3208512996">
         <span class="h2">
          First-line therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children with newly-diagnosed CAE, we recommend
         <a class="drug drug_pediatric" data-topicid="13288" href="/z/d/drug information/13288.html" rel="external">
          ethosuximide
         </a>
         rather than
         <a class="drug drug_pediatric" data-topicid="12873" href="/z/d/drug information/12873.html" rel="external">
          valproic acid
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12542" href="/z/d/drug information/12542.html" rel="external">
          lamotrigine
         </a>
         as first-line therapy [
         <a href="#rid90">
          90,91
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ethosuximide
         </strong>
         <strong>
          dosing and adverse effects
         </strong>
         – The typical starting dose of
         <a class="drug drug_pediatric" data-topicid="13288" href="/z/d/drug information/13288.html" rel="external">
          ethosuximide
         </a>
         is 5 to 10 mg/kg per day in two divided doses for children younger than six years, and 250 mg twice daily for children six years of age and older. The usual maintenance dose is 15 to 40 mg/kg per day in divided doses. Serum levels of ethosuximide should be checked initially after one to three weeks, with a goal therapeutic concentration of 40 to 100 micrograms/mL (280 to 700 micromol/L). The most common side effects include nausea, vomiting, sleep disturbance, drowsiness, and hyperactivity. (See
         <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">
          "Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Ethosuximide'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Assessing response
         </strong>
         – Initial monotherapy should not be abandoned before ensuring that the maximum tolerated dose has been achieved. In most cases, response can be assessed clinically, as typical absence seizures are typically easy to follow once they are recognized. In some cases, EEG can be used to aid in determining the response to therapy if the clinical improvement is unclear after two to four weeks of therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supportive evidence
         </strong>
         – The use of
         <a class="drug drug_pediatric" data-topicid="13288" href="/z/d/drug information/13288.html" rel="external">
          ethosuximide
         </a>
         as first-line therapy is supported by results of a randomized, double-blind trial that compared the efficacy and tolerability of ethosuximide,
         <a class="drug drug_pediatric" data-topicid="12873" href="/z/d/drug information/12873.html" rel="external">
          valproate
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="12542" href="/z/d/drug information/12542.html" rel="external">
          lamotrigine
         </a>
         in 453 children with CAE. After 16 weeks of treatment, ethosuximide and valproate were significantly more effective than lamotrigine (16-week freedom-from-seizure rates of 53, 58, and 29 percent, respectively), and the rate of drug discontinuation for adverse effects was similar among the three groups [
         <a href="#rid92">
          92
         </a>
         ]. However, valproate was associated with more frequent attentional dysfunction than ethosuximide (49 versus 33 percent) [
         <a href="#rid67">
          67,92
         </a>
         ]. A follow-up study that assessed the same parameters after 12 months of treatment also confirmed that ethosuximide had better efficacy than lamotrigine and fewer side effects than valproate [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3994818121">
         <span class="h2">
          Patients who fail or do not tolerate first-line therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who have inadequate control of typical absence seizures or intolerable side effects on
         <a class="drug drug_pediatric" data-topicid="13288" href="/z/d/drug information/13288.html" rel="external">
          ethosuximide
         </a>
         , we suggest switching to
         <a class="drug drug_pediatric" data-topicid="12873" href="/z/d/drug information/12873.html" rel="external">
          valproate
         </a>
         monotherapy, although
         <a class="drug drug_pediatric" data-topicid="12542" href="/z/d/drug information/12542.html" rel="external">
          lamotrigine
         </a>
         may be a better alternative in females of childbearing age based on the increasingly well-characterized fetal risks of valproate. (See
         <a class="medical medical_review" href="/z/d/html/2218.html" rel="external">
          "Risks associated with epilepsy during pregnancy and the postpartum period", section on 'Valproate'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2218.html" rel="external">
          "Risks associated with epilepsy during pregnancy and the postpartum period", section on 'Neurodevelopmental risks'
         </a>
         .)
        </p>
        <p>
         For patients who develop generalized tonic-clonic seizures (GTCS) on
         <a class="drug drug_pediatric" data-topicid="13288" href="/z/d/drug information/13288.html" rel="external">
          ethosuximide
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12873" href="/z/d/drug information/12873.html" rel="external">
          valproate
         </a>
         is also an effective second-line therapy, either as an add-on agent or as monotherapy, since it may be effective for both seizure types [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p>
         Additional options for refractory CAE include
         <a class="drug drug_pediatric" data-topicid="12851" href="/z/d/drug information/12851.html" rel="external">
          topiramate
         </a>
         [
         <a href="#rid93">
          93
         </a>
         ], benzodiazepines [
         <a href="#rid50">
          50
         </a>
         ],
         <a class="drug drug_pediatric" data-topicid="13213" href="/z/d/drug information/13213.html" rel="external">
          acetazolamide
         </a>
         [
         <a href="#rid50">
          50
         </a>
         ],
         <a class="drug drug_pediatric" data-topicid="12612" href="/z/d/drug information/12612.html" rel="external">
          zonisamide
         </a>
         [
         <a href="#rid94">
          94
         </a>
         ], ketogenic dietary therapy, and vagus nerve stimulation. For all of these options, trials that formally evaluate their effectiveness and side effect profile are lacking [
         <a href="#rid95">
          95
         </a>
         ]; however, observational data suggest benefit.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Valproate
         </strong>
         <strong>
          dosing and adverse effects
         </strong>
         – The starting dose of
         <a class="drug drug_pediatric" data-topicid="12873" href="/z/d/drug information/12873.html" rel="external">
          valproate
         </a>
         is 15 mg/kg per day in one to three divided doses. The dose is increased by 5 to 10 mg/kg per day at weekly intervals until seizures are controlled or side effects preclude further increases. Daily doses &gt;250 mg should be given in divided doses. The usual maintenance dose is 30 to 60 mg/kg per day in two to three divided doses. A serum valproate level should be checked one to two weeks after the initial dose but can be checked as soon as three to four days after initiation or dose adjustment; the usual range of therapeutic concentrations is 50 to 125 micrograms/mL (346 to 875 micromol/L).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The most common adverse effects of
         <a class="drug drug_pediatric" data-topicid="12873" href="/z/d/drug information/12873.html" rel="external">
          valproate
         </a>
         include nausea, vomiting, hair loss, easy bruising, and tremor  (
         <a class="graphic graphic_table graphicRef59755 graphicRef78896" href="/z/d/graphic/59755.html" rel="external">
          table 3A-B
         </a>
         ). Valproate is also associated with weight gain, obesity, and insulin resistance. Nocturnal enuresis, likely related to impaired sleep efficiency, has been reported in children. Approximately 5 to 10 percent of patients develop alanine aminotransferase (ALT) elevations, usually asymptomatic, during long-term valproate therapy. More serious forms of toxicity include hyperammonemic encephalopathy, acute hepatocellular injury, acute pancreatitis, thrombocytopenia, and teratogenicity. (See
         <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">
          "Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Valproate'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lamotrigine
         </strong>
         <strong>
          dosing and adverse effects
         </strong>
         – For children and adolescents 2.5 to 13 years of age, the initial dose is 0.3 mg/kg per day in two divided doses for two weeks, then 0.6 mg/kg per day for two weeks; titrated weekly to effect and tolerability to a maximum daily dose of 12 mg/kg per day or 600 mg/day (whichever is less). Multiple titration strategies have been reported. In the trial discussed above (n = 453), the initial
         <a class="drug drug_pediatric" data-topicid="12542" href="/z/d/drug information/12542.html" rel="external">
          lamotrigine
         </a>
         dose was 0.3 mg/kg per day for two weeks, followed by 0.6 mg/kg per day for two weeks [
         <a href="#rid92">
          92
         </a>
         ]. Thereafter, the dose was increased at weekly intervals until efficacy or intolerability in 0.6 mg/kg per day increments up to 3 mg/kg per day for one week (week 8), then increased to 4.5 mg/kg per day for two weeks, then 7 mg/kg per day for two weeks, then 9 mg/kg per day for two weeks, and then finally 12 mg/kg per day (week 15); the mean final dose was 9.7±6.3 mg/kg per day.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Neurotoxic adverse effects of
         <a class="drug drug_pediatric" data-topicid="12542" href="/z/d/drug information/12542.html" rel="external">
          lamotrigine
         </a>
         are predominantly dizziness and somnolence. Systemic adverse effects include rash and nausea. Rare but potentially life-threatening adverse effects include Stevens-Johnson syndrome, toxic epidermal necrolysis, and angioedema. The risk of serious rash may be increased if lamotrigine is started at a dose that exceeds the recommended initial dose, if dose escalation is too rapid, or if lamotrigine is coadministered with
         <a class="drug drug_pediatric" data-topicid="12873" href="/z/d/drug information/12873.html" rel="external">
          valproate
         </a>
         . Lamotrigine is rarely associated with acute multiorgan failure and hypersensitivity reactions, including drug reaction with eosinophilia and systemic symptoms (DRESS), hemophagocytic lymphohistiocytosis, and disseminated intravascular coagulation. Due to its pro-arrhythmic potential, lamotrigine should be avoided in patients who have cardiac conduction disorders. (See
         <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">
          "Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Lamotrigine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evidence supporting second-line therapies
         </strong>
         – In the randomized trial comparing
         <a class="drug drug_pediatric" data-topicid="13288" href="/z/d/drug information/13288.html" rel="external">
          ethosuximide
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12873" href="/z/d/drug information/12873.html" rel="external">
          valproate
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="12542" href="/z/d/drug information/12542.html" rel="external">
          lamotrigine
         </a>
         described above, 208 patients who experienced treatment failure during the double-blind phase were enrolled in an open-label extension study and randomly assigned to second monotherapy with one of the remaining two study drugs [
         <a href="#rid96">
          96
         </a>
         ]. After 16 to 20 weeks of therapy, freedom-from-seizure rates were higher for ethosuximide and valproate (53 and 58 percent, respectively) than for lamotrigine (29 percent). For ethosuximide and valproate, these response rates are comparable with those observed in the first-line setting [
         <a href="#rid92">
          92
         </a>
         ] and support the practice of using second monotherapy rather than add-on therapy in children who do not respond adequately to first-line therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         CAE may respond to ketogenic dietary therapy when antiseizure medications are incompletely effective [
         <a href="#rid97">
          97,98
         </a>
         ]. In a case series of 21 patients with childhood and juvenile absence epilepsy, use of the classic ketogenic diet or modified Atkins diet was associated with a &gt;50 percent seizure reduction in 82 percent and complete seizure remission in 19 percent [
         <a href="#rid97">
          97
         </a>
         ]. In the same report, a review of published studies that included 133 patients with absence epilepsy found similar results; 69 percent had a &gt;50 percent seizure reduction and 34 percent became seizure-free. (See
         <a class="medical medical_review" href="/z/d/html/14438.html" rel="external">
          "Ketogenic dietary therapies for the treatment of epilepsy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Vagus nerve stimulation has been shown to reduce seizure frequency in some patients with CAE and refractory absences [
         <a href="#rid99">
          99,100
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2229.html" rel="external">
          "Vagus nerve stimulation therapy for the treatment of epilepsy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There are mixed reports from small studies with regard to
         <a class="drug drug_pediatric" data-topicid="12910" href="/z/d/drug information/12910.html" rel="external">
          levetiracetam
         </a>
         in CAE, with one study suggesting efficacy [
         <a href="#rid101">
          101
         </a>
         ], another reporting aggravation of absences in certain patients [
         <a href="#rid102">
          102
         </a>
         ], and a third study of 72 children showing apparent benefit in 25 percent but a high rate of discontinuation (74 percent) due to poor seizure control and/or side effects [
         <a href="#rid103">
          103
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3777258">
         <span class="h2">
          Drugs to avoid
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several antiseizure medications have the potential to aggravate absence seizures in patients with CAE and should be avoided. These include
         <a class="drug drug_pediatric" data-topicid="13113" href="/z/d/drug information/13113.html" rel="external">
          carbamazepine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13101" href="/z/d/drug information/13101.html" rel="external">
          vigabatrin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13330" href="/z/d/drug information/13330.html" rel="external">
          gabapentin
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="12841" href="/z/d/drug information/12841.html" rel="external">
          tiagabine
         </a>
         .
         <a class="drug drug_pediatric" data-topicid="12702" href="/z/d/drug information/12702.html" rel="external">
          Phenytoin
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">
          phenobarbital
         </a>
         are known for their ineffectiveness in treating absences and should also be avoided [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3777313">
         <span class="h2">
          Duration of therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In most cases, seizures respond well to first-line drug therapy and remit before puberty. Antiseizure medication therapy should be continued for a minimum of two years of seizure freedom. After this period, progressive tapering of antiseizure medications can be considered.
        </p>
        <p class="headingAnchor" id="H383785515">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         CAE is typically responsive to antiseizure medication (see
         <a class="local">
          'Treatment'
         </a>
         above). Although often perceived as a benign form of epilepsy, observational studies with long-term follow-up describe a wide range of seizure outcomes in children with CAE. Much of the variability likely relates to differences in diagnostic classification over the years, however, and the inclusion of patients who ultimately go on to have juvenile myoclonic epilepsy (JME) or other syndromes associated with lower rates of seizure remission.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Seizure-free remission
         </strong>
         – Seizure-free remission occurs by early adolescence in ≥60 percent of patients with CAE [
         <a href="#rid3">
          3,53,55,104,105
         </a>
         ]. In one study that included 72 children initially diagnosed with CAE, approximately two-thirds of patients were seizure-free at a minimum follow-up of nine years after seizure onset [
         <a href="#rid53">
          53
         </a>
         ]. Seventeen percent were still having seizures but did not take medications. Forty-four percent of patients not in remission had progressed to JME. Significant factors predicting no remission included cognitive difficulties at onset, absence status epilepticus before or during drug treatment, generalized tonic-clonic or myoclonic seizures after treatment onset, abnormal background on initial EEG, and a history of generalized seizures in first-degree relatives.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In another study, over 90 percent of children with CAE diagnosed according to the 1989 International League Against Epilepsy (ILAE) classification were seizure-free after a mean follow-up of 15 years [
         <a href="#rid55">
          55
         </a>
         ]. Those who fulfilled the 2005 criteria had fewer generalized tonic-clonic seizures (GTCS), but their final overall outcome was not significantly different from those who did not. The total duration of epilepsy and the mean age at final remission were 3.9 and 9.5 years, respectively. Epilepsy duration was longer in those children who had become seizure-free more than six months after treatment initiation [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prolonged refractory epilepsy
         </strong>
         – A relatively small proportion of children with typical absence seizures are refractory to typical therapeutic approaches for a prolonged period. In one study of 92 such children with refractory typical absence seizures, approximately 50 percent eventually achieved prolonged seizure freedom with or without antiseizure medications [
         <a href="#rid106">
          106
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evolution to other IGE syndromes
         </strong>
         – A minority of patients with CAE do not achieve seizure-free remission, and in some of these cases, CAE evolves to another idiopathic generalized epilepsy (IGE) such as JME.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Persistence of comorbidities
         </strong>
         – Despite favorable rates of seizure freedom by adolescence, psychiatric and behavioral comorbidities are common in children with CAE and can persist even in the absence of ongoing seizures. Recognition of comorbid diagnoses such as attention deficit hyperactivity disorder (ADHD) is important because effective treatments exist, and ADHD has been associated with decreased health-related quality of life in children with epilepsy. This is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/129781.html" rel="external">
          "Epilepsy in children: Comorbidities, complications, and outcomes", section on 'Psychiatric and behavioral health'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4071825272">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113981.html" rel="external">
          "Society guideline links: Seizures and epilepsy in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H383785521">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetics
         </strong>
         – Childhood absence epilepsy (CAE) is an idiopathic generalized epilepsy syndrome  (
         <a class="graphic graphic_figure graphicRef141084" href="/z/d/graphic/141084.html" rel="external">
          figure 1
         </a>
         ). A polygenic cause is suggested by family and twin studies; single-gene defects that reliably result in CAE have not been identified. (See
         <a class="local">
          'Etiology and genetics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – CAE is a common form of pediatric epilepsy, accounting for 12 to 18 percent of all cases of childhood-onset epilepsy. The prevalence of CAE is higher in girls (60 to 75 percent of cases) than in boys. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Presentation
         </strong>
         – CAE is characterized by typical absence seizures occurring in otherwise healthy children. The median age of onset is six years; most patients present between the ages of 4 and 10 years. (See
         <a class="local">
          'Clinical presentation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Seizure semiology
         </strong>
         – The typical absence seizure is characterized by abrupt onset and termination, profound impairment of consciousness, and an average duration of 10 seconds. Common features include arrest in activity, staring, repetitive eyelid movements, and automatisms. (See
         <a class="local">
          'Seizure semiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Comorbidities
         </strong>
         – Most children with CAE have normal development and intellect; however, neurocognitive testing may detect mild deficits, particularly in executive function. Attention deficit hyperactivity disorder, mood disorders, and learning disorders are common comorbidities. (See
         <a class="local">
          'Behavioral and psychiatric comorbidities'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
         – The evaluation of patients with suspected absence seizures includes (see
         <a class="local">
          'Evaluation'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Diagnostic hyperventilation, which can provoke absence seizures in most untreated patients with CAE (see
         <a class="local">
          'Hyperventilation'
         </a>
         above)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Sleep-deprived video-EEG that includes both intermittent photic stimulation and hyperventilation (see
         <a class="local">
          'Electroencephalography'
         </a>
         above)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Brain imaging is not necessary in otherwise typical cases (see
         <a class="local">
          'Neuroimaging'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          EEG
         </strong>
         – The classic EEG pattern of CAE consists of discrete periods of generalized 3 Hz (range 2.5 to 5.5 Hz) spike-wave discharges that are easily provoked by hyperventilation. (See
         <a class="local">
          'Electroencephalography'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of CAE requires typical absence seizures and an EEG with paroxysms of 3 Hz (range 2.5 to 4.0 Hz) generalized spike-wave discharges at the start of the absence seizure  (
         <a class="graphic graphic_table graphicRef141085" href="/z/d/graphic/141085.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Diagnosis'
         </a>
         above and
         <a class="local">
          'Mandatory criteria'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Alert criteria are features that are absent in most patients with CAE; their presence reduces confidence in the diagnosis and should prompt further investigations. Examples include absences occurring less than daily in an untreated patient, a variety of atypical EEG findings, and others listed above. (See
         <a class="local">
          'Alert criteria'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Features not compatible with CAE include certain seizure types (eg, prominent myoclonic seizures, atonic seizures, atypical absence seizures, focal impaired awareness seizures), an EEG with diffuse background slowing, age at onset less than 2 years or greater than 13 years, and others listed above. (See
         <a class="local">
          'Exclusionary criteria'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnoses
         </strong>
         – The differential diagnosis of typical absence seizures in a child includes nonepileptic staring spells, which can be seen in association with normal development, attention deficit hyperactivity disorder, autism, and intellectual disability.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Typical absence seizures may also be seen in other generalized epilepsy syndromes such as juvenile absence epilepsy  (
         <a class="graphic graphic_table graphicRef141086" href="/z/d/graphic/141086.html" rel="external">
          table 2
         </a>
         ) and juvenile myoclonic epilepsy. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For children with newly-diagnosed CAE, we recommend
         <a class="drug drug_pediatric" data-topicid="13288" href="/z/d/drug information/13288.html" rel="external">
          ethosuximide
         </a>
         rather than
         <a class="drug drug_pediatric" data-topicid="12873" href="/z/d/drug information/12873.html" rel="external">
          valproic acid
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12542" href="/z/d/drug information/12542.html" rel="external">
          lamotrigine
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Ethosuximide is well tolerated and associated with complete seizure freedom in over half of children after 16 weeks of therapy. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For children who fail or do not tolerate first-line therapy with
         <a class="drug drug_pediatric" data-topicid="13288" href="/z/d/drug information/13288.html" rel="external">
          ethosuximide
         </a>
         , we suggest switching to
         <a class="drug drug_pediatric" data-topicid="12873" href="/z/d/drug information/12873.html" rel="external">
          valproate
         </a>
         monotherapy (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ).
         <a class="drug drug_pediatric" data-topicid="12542" href="/z/d/drug information/12542.html" rel="external">
          Lamotrigine
         </a>
         is a reasonable alternative in females of childbearing age based on the fetal risks of valproate. (See
         <a class="local">
          'Patients who fail or do not tolerate first-line therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – In most cases, seizures respond well to the first-line drug monotherapy and remit before puberty, without cognitive sequelae. A minority of patients with CAE do not achieve seizure-free remission, and in some of these cases, CAE evolves to another syndrome such as juvenile myoclonic epilepsy. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010; 51:676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017; 58:512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirsch E, French J, Scheffer IE, et al. ILAE definition of the Idiopathic Generalized Epilepsy Syndromes: Position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia 2022; 63:1475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loiseau P, Duché B, Pédespan JM. Absence epilepsies. Epilepsia 1995; 36:1182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corey LA, Pellock JM, Kjeldsen MJ, Nakken KO. Importance of genetic factors in the occurrence of epilepsy syndrome type: a twin study. Epilepsy Res 2011; 97:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sugimoto Y, Morita R, Amano K, et al. Childhood absence epilepsy in 8q24: refinement of candidate region and construction of physical map. Genomics 2000; 68:264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fong GC, Shah PU, Gee MN, et al. Childhood absence epilepsy with tonic-clonic seizures and electroencephalogram 3-4-Hz spike and multispike-slow wave complexes: linkage to chromosome 8q24. Am J Hum Genet 1998; 63:1117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Kovel CG, Trucks H, Helbig I, et al. Recurrent microdeletions at 15q11.2 and 16p13.11 predispose to idiopathic generalized epilepsies. Brain 2010; 133:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Helbig I, Mefford HC, Sharp AJ, et al. 15q13.3 microdeletions increase risk of idiopathic generalized epilepsy. Nat Genet 2009; 41:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiang Y, Zhang Y, Zhang P, et al. NIPA2 located in 15q11.2 is mutated in patients with childhood absence epilepsy. Hum Genet 2012; 131:1217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gurba KN, Hernandez CC, Hu N, Macdonald RL. GABRB3 mutation, G32R, associated with childhood absence epilepsy alters α1β3γ2L γ-aminobutyric acid type A (GABAA) receptor expression and channel gating. J Biol Chem 2012; 287:12083.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hernandez CC, Gurba KN, Hu N, Macdonald RL. The GABRA6 mutation, R46W, associated with childhood absence epilepsy, alters 6β22 and 6β2 GABA(A) receptor channel gating and expression. J Physiol 2011; 589:5857.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tanaka M, Olsen RW, Medina MT, et al. Hyperglycosylation and reduced GABA currents of mutated GABRB3 polypeptide in remitting childhood absence epilepsy. Am J Hum Genet 2008; 82:1249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Urak L, Feucht M, Fathi N, et al. A GABRB3 promoter haplotype associated with childhood absence epilepsy impairs transcriptional activity. Hum Mol Genet 2006; 15:2533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maljevic S, Krampfl K, Cobilanschi J, et al. A mutation in the GABA(A) receptor alpha(1)-subunit is associated with absence epilepsy. Ann Neurol 2006; 59:983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson R, Taske N, Sander T, et al. Linkage analysis between childhood absence epilepsy and genes encoding GABAA and GABAB receptors, voltage-dependent calcium channels, and the ECA1 region on chromosome 8q. Epilepsy Res 2002; 48:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallace RH, Marini C, Petrou S, et al. Mutant GABA(A) receptor gamma2-subunit in childhood absence epilepsy and febrile seizures. Nat Genet 2001; 28:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feucht M, Fuchs K, Pichlbauer E, et al. Possible association between childhood absence epilepsy and the gene encoding GABRB3. Biol Psychiatry 1999; 46:997.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yalçın O. Genes and molecular mechanisms involved in the epileptogenesis of idiopathic absence epilepsies. Seizure 2012; 21:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Everett KV, Chioza B, Aicardi J, et al. Linkage and association analysis of CACNG3 in childhood absence epilepsy. Eur J Hum Genet 2007; 15:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vitko I, Bidaud I, Arias JM, et al. The I-II loop controls plasma membrane expression and gating of Ca(v)3.2 T-type Ca2+ channels: a paradigm for childhood absence epilepsy mutations. J Neurosci 2007; 27:322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liang J, Zhang Y, Chen Y, et al. Common polymorphisms in the CACNA1H gene associated with childhood absence epilepsy in Chinese Han population. Ann Hum Genet 2007; 71:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liang J, Zhang Y, Wang J, et al. New variants in the CACNA1H gene identified in childhood absence epilepsy. Neurosci Lett 2006; 406:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen Y, Lu J, Pan H, et al. Association between genetic variation of CACNA1H and childhood absence epilepsy. Ann Neurol 2003; 54:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Everett K, Chioza B, Aicardi J, et al. Linkage and mutational analysis of CLCN2 in childhood absence epilepsy. Epilepsy Res 2007; 75:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haug K, Warnstedt M, Alekov AK, et al. Mutations in CLCN2 encoding a voltage-gated chloride channel are associated with idiopathic generalized epilepsies. Nat Genet 2003; 33:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kananura C, Haug K, Sander T, et al. A splice-site mutation in GABRG2 associated with childhood absence epilepsy and febrile convulsions. Arch Neurol 2002; 59:1137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang J, Zhang Y, Liang J, et al. CACNA1I is not associated with childhood absence epilepsy in the Chinese Han population. Pediatr Neurol 2006; 35:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen Y, Lu J, Zhang Y, et al. T-type calcium channel gene alpha (1G) is not associated with childhood absence epilepsy in the Chinese Han population. Neurosci Lett 2003; 341:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chioza B, Everett K, Aschauer H, et al. Evaluation of CACNA1H in European patients with childhood absence epilepsy. Epilepsy Res 2006; 69:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arsov T, Mullen SA, Rogers S, et al. Glucose transporter 1 deficiency in the idiopathic generalized epilepsies. Ann Neurol 2012; 72:807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suls A, Mullen SA, Weber YG, et al. Early-onset absence epilepsy caused by mutations in the glucose transporter GLUT1. Ann Neurol 2009; 66:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muhle H, Helbig I, Frøslev TG, et al. The role of SLC2A1 in early onset and childhood absence epilepsies. Epilepsy Res 2013; 105:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Byrne S, Kearns J, Carolan R, et al. Refractory absence epilepsy associated with GLUT-1 deficiency syndrome. Epilepsia 2011; 52:1021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mullen SA, Suls A, De Jonghe P, et al. Absence epilepsies with widely variable onset are a key feature of familial GLUT1 deficiency. Neurology 2010; 75:432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agostinelli S, Traverso M, Accorsi P, et al. Early-onset absence epilepsy: SLC2A1 gene analysis and treatment evolution. Eur J Neurol 2013; 20:856.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crunelli V, Lőrincz ML, McCafferty C, et al. Clinical and experimental insight into pathophysiology, comorbidity and therapy of absence seizures. Brain 2020; 143:2341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Luijtelaar G, Hramov A, Sitnikova E, Koronovskii A. Spike-wave discharges in WAG/Rij rats are preceded by delta and theta precursor activity in cortex and thalamus. Clin Neurophysiol 2011; 122:687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Luijtelaar G, Sitnikova E, Littjohann A. On the origin and suddenness of absences in genetic absence models. Clin EEG Neurosci 2011; 42:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tenney JR, Fujiwara H, Horn PS, et al. Focal corticothalamic sources during generalized absence seizures: a MEG study. Epilepsy Res 2013; 106:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Depaulis A, Charpier S. Pathophysiology of absence epilepsy: Insights from genetic models. Neurosci Lett 2018; 667:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berman R, Negishi M, Vestal M, et al. Simultaneous EEG, fMRI, and behavior in typical childhood absence seizures. Epilepsia 2010; 51:2011.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bai X, Vestal M, Berman R, et al. Dynamic time course of typical childhood absence seizures: EEG, behavior, and functional magnetic resonance imaging. J Neurosci 2010; 30:5884.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Masterton RA, Carney PW, Abbott DF, Jackson GD. Absence epilepsy subnetworks revealed by event-related independent components analysis of functional magnetic resonance imaging. Epilepsia 2013; 54:801.
          </a>
         </li>
         <li class="breakAll">
          Crunelli V, Leresche N, Cope DW. GABA-A Receptor Function in Typical Absence Seizures. In: Jasper's Basic Mechanisms of the Epilepsies, 4th, Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV (Eds), Bethesda 2012.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berg AT, Shinnar S, Levy SR, et al. How well can epilepsy syndromes be identified at diagnosis? A reassessment 2 years after initial diagnosis. Epilepsia 2000; 41:1269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berg AT, Levy SR, Testa FM, Shinnar S. Classification of childhood epilepsy syndromes in newly diagnosed epilepsy: interrater agreement and reasons for disagreement. Epilepsia 1999; 40:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olsson I. Epidemiology of absence epilepsy. I. Concept and incidence. Acta Paediatr Scand 1988; 77:860.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loiseau J, Loiseau P, Guyot M, et al. Survey of seizure disorders in the French southwest. I. Incidence of epileptic syndromes. Epilepsia 1990; 31:391.
          </a>
         </li>
         <li class="breakAll">
          Medina M, Bureau M, Hirsch E, Panayiotopoulos C. Childhood absence epilepsy. In: Epileptic Syndromes in Infancy, Childhood and Adolescence, 5th ed, Bureau M, Genton P, Dravet C, et al (Eds), John Libbey Eurotext Ltd, London 2012. p.277.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larsson K, Eeg-Olofsson O. A population based study of epilepsy in children from a Swedish county. Eur J Paediatr Neurol 2006; 10:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sadleir LG, Farrell K, Smith S, et al. Electroclinical features of absence seizures in childhood absence epilepsy. Neurology 2006; 67:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wirrell EC, Camfield CS, Camfield PR, et al. Long-term prognosis of typical childhood absence epilepsy: remission or progression to juvenile myoclonic epilepsy. Neurology 1996; 47:912.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kessler SK, Shinnar S, Cnaan A, et al. Pretreatment seizure semiology in childhood absence epilepsy. Neurology 2017; 89:673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Callenbach PM, Bouma PA, Geerts AT, et al. Long-term outcome of childhood absence epilepsy: Dutch Study of Epilepsy in Childhood. Epilepsy Res 2009; 83:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shinnar S, Cnaan A, Hu F, et al. Long-term outcomes of generalized tonic-clonic seizures in a childhood absence epilepsy trial. Neurology 2015; 85:1108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caplan R, Siddarth P, Stahl L, et al. Childhood absence epilepsy: behavioral, cognitive, and linguistic comorbidities. Epilepsia 2008; 49:1838.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hermann B, Jones J, Dabbs K, et al. The frequency, complications and aetiology of ADHD in new onset paediatric epilepsy. Brain 2007; 130:3135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abarrategui B, Parejo-Carbonell B, García García ME, et al. The cognitive phenotype of idiopathic generalized epilepsy. Epilepsy Behav 2018; 89:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson DC, Dabbs K, Walker NM, et al. The neuropsychological and academic substrate of new/recent-onset epilepsies. J Pediatr 2013; 162:1047.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conant LL, Wilfong A, Inglese C, Schwarte A. Dysfunction of executive and related processes in childhood absence epilepsy. Epilepsy Behav 2010; 18:414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berg AT, Langfitt JT, Testa FM, et al. Global cognitive function in children with epilepsy: a community-based study. Epilepsia 2008; 49:608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berg AT, Langfitt JT, Testa FM, et al. Residual cognitive effects of uncomplicated idiopathic and cryptogenic epilepsy. Epilepsy Behav 2008; 13:614.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berg AT, Smith SN, Frobish D, et al. Special education needs of children with newly diagnosed epilepsy. Dev Med Child Neurol 2005; 47:749.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eapen M, Iype M, Saradakutty G, et al. Childhood Absence Epilepsy- Electroclinical Profile and Prevalence of Attention-Deficit/Hyperactivity Disorder Among a Cohort of 47 Children. Pediatr Neurol 2024; 150:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cerminara C, D'Agati E, Casarelli L, et al. Attention impairment in childhood absence epilepsy: an impulsivity problem? Epilepsy Behav 2013; 27:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Masur D, Shinnar S, Cnaan A, et al. Pretreatment cognitive deficits and treatment effects on attention in childhood absence epilepsy. Neurology 2013; 81:1572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dlugos D, Shinnar S, Cnaan A, et al. Pretreatment EEG in childhood absence epilepsy: associations with attention and treatment outcome. Neurology 2013; 81:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gruenbaum BF, Sandhu MRS, Bertasi RAO, et al. Absence seizures and their relationship to depression and anxiety: Evidence for bidirectionality. Epilepsia 2021; 62:1041.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kessler SK, McGinnis E. A Practical Guide to Treatment of Childhood Absence Epilepsy. Paediatr Drugs 2019; 21:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia 2013; 54:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salvati KA, Beenhakker MP. Out of thin air: Hyperventilation-triggered seizures. Brain Res 2019; 1703:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mariani E, Rossi LN, Vajani S. Interictal paroxysmal EEG abnormalities in childhood absence epilepsy. Seizure 2011; 20:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sadleir LG, Scheffer IE, Smith S, et al. EEG features of absence seizures in idiopathic generalized epilepsy: impact of syndrome, age, and state. Epilepsia 2009; 50:1572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoshinaga H, Ohtsuka Y, Tamai K, et al. EEG in childhood absence epilepsy. Seizure 2004; 13:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lagae L, Pauwels J, Monté CP, et al. Frontal absences in children. Eur J Paediatr Neurol 2001; 5:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan CH, Briellmann RS, Pell GS, et al. Thalamic atrophy in childhood absence epilepsy. Epilepsia 2006; 47:399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caplan R, Levitt J, Siddarth P, et al. Frontal and temporal volumes in Childhood Absence Epilepsy. Epilepsia 2009; 50:2466.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schreibman Cohen A, Daley M, Siddarth P, et al. Amygdala volumes in childhood absence epilepsy. Epilepsy Behav 2009; 16:436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim EH, Shim WH, Lee JS, et al. Altered Structural Network in Newly Onset Childhood Absence Epilepsy. J Clin Neurol 2020; 16:573.
          </a>
         </li>
         <li class="breakAll">
          Panayiotopoulos C. Absence epilepsies. In: Epilepsy: a comprehensive textbook, Engel Jr. J, Pedley T (Eds), Lippincott-Raven, Philadelphia 1997. p.2327.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larsen J, Johannesen KM, Ek J, et al. The role of SLC2A1 mutations in myoclonic astatic epilepsy and absence epilepsy, and the estimated frequency of GLUT1 deficiency syndrome. Epilepsia 2015; 56:e203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Striano P, Weber YG, Toliat MR, et al. GLUT1 mutations are a rare cause of familial idiopathic generalized epilepsy. Neurology 2012; 78:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verrotti A, D'Egidio C, Agostinelli S, Gobbi G. Glut1 deficiency: when to suspect and how to diagnose? Eur J Paediatr Neurol 2012; 16:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alter AS, Engelstad K, Hinton VJ, et al. Long-term clinical course of Glut1 deficiency syndrome. J Child Neurol 2015; 30:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pascual JM, Liu P, Mao D, et al. Triheptanoin for glucose transporter type I deficiency (G1D): modulation of human ictogenesis, cerebral metabolic rate, and cognitive indices by a food supplement. JAMA Neurol 2014; 71:1255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mochel F, Hainque E, Gras D, et al. Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency. J Neurol Neurosurg Psychiatry 2016; 87:550.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zawar I, Knight EP. Epilepsy With Eyelid Myoclonia (Jeavons Syndrome). Pediatr Neurol 2021; 121:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Specchio N, Wirrell EC, Scheffer IE, et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: Position paper by the ILAE Task Force on Nosology and Definitions. Epilepsia 2022; 63:1398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brigo F, Igwe SC, Lattanzi S. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database Syst Rev 2021; 1:CD003032.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2018; 91:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 2010; 362:790.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cross JH. Topiramate monotherapy for childhood absence seizures: an open label pilot study. Seizure 2002; 11:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilfong A, Schultz R. Zonisamide for absence seizures. Epilepsy Res 2005; 64:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013; 54:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cnaan A, Shinnar S, Arya R, et al. Second monotherapy in childhood absence epilepsy. Neurology 2017; 88:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groomes LB, Pyzik PL, Turner Z, et al. Do patients with absence epilepsy respond to ketogenic diets? J Child Neurol 2011; 26:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thammongkol S, Vears DF, Bicknell-Royle J, et al. Efficacy of the ketogenic diet: which epilepsies respond? Epilepsia 2012; 53:e55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arya R, Greiner HM, Lewis A, et al. Vagus nerve stimulation for medically refractory absence epilepsy. Seizure 2013; 22:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haddad L, Pawar K, Perdew CH, et al. Efficacy and Tolerability of Ultra Rapid Duty Cycling Vagus Nerve Stimulation for Medically Refractory Absence Seizures. Pediatr Neurol 2023; 147:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verrotti A, Cerminara C, Domizio S, et al. Levetiracetam in absence epilepsy. Dev Med Child Neurol 2008; 50:850.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Auvin S, Chhun S, Berquin P, et al. Aggravation of absence seizure related to levetiracetam. Eur J Paediatr Neurol 2011; 15:508.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nolan D, Lester SG, Rau SM, Shellhaas RA. Clinical Use and Efficacy of Levetiracetam for Absence Epilepsies. J Child Neurol 2019; 34:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valentin A, Hindocha N, Osei-Lah A, et al. Idiopathic generalized epilepsy with absences: syndrome classification. Epilepsia 2007; 48:2187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morse E, Giblin K, Chung MH, et al. Historical trend toward improved long-term outcome in childhood absence epilepsy. Epilepsy Res 2019; 152:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franzoni E, Matricardi S, Di Pisa V, et al. Refractory absence seizures: An Italian multicenter retrospective study. Eur J Paediatr Neurol 2015; 19:660.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 14450 Version 28.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20196795" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28276062" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35503716" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : ILAE definition of the Idiopathic Generalized Epilepsy Syndromes: Position statement by the ILAE Task Force on Nosology and Definitions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7489694" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Absence epilepsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21885256" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Importance of genetic factors in the occurrence of epilepsy syndrome type: a twin study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10995568" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Childhood absence epilepsy in 8q24: refinement of candidate region and construction of physical map.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9758624" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Childhood absence epilepsy with tonic-clonic seizures and electroencephalogram 3-4-Hz spike and multispike-slow wave complexes: linkage to chromosome 8q24.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19843651" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Recurrent microdeletions at 15q11.2 and 16p13.11 predispose to idiopathic generalized epilepsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19136953" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : 15q13.3 microdeletions increase risk of idiopathic generalized epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22367439" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : NIPA2 located in 15q11.2 is mutated in patients with childhood absence epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22303015" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : GABRB3 mutation, G32R, associated with childhood absence epilepsy altersα1β3γ2Lγ-aminobutyric acid type A (GABAA) receptor expression and channel gating.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21930603" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The GABRA6 mutation, R46W, associated with childhood absence epilepsy, alters 6β22 and 6β2 GABA(A) receptor channel gating and expression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18514161" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Hyperglycosylation and reduced GABA currents of mutated GABRB3 polypeptide in remitting childhood absence epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16835263" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : A GABRB3 promoter haplotype associated with childhood absence epilepsy impairs transcriptional activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16718694" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : A mutation in the GABA(A) receptor alpha(1)-subunit is associated with absence epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11904235" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Linkage analysis between childhood absence epilepsy and genes encoding GABAA and GABAB receptors, voltage-dependent calcium channels, and the ECA1 region on chromosome 8q.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11326275" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Mutant GABA(A) receptor gamma2-subunit in childhood absence epilepsy and febrile seizures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10509183" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Possible association between childhood absence epilepsy and the gene encoding GABRB3.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22206818" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Genes and molecular mechanisms involved in the epileptogenesis of idiopathic absence epilepsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17264864" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Linkage and association analysis of CACNG3 in childhood absence epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17215393" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The I-II loop controls plasma membrane expression and gating of Ca(v)3.2 T-type Ca2+ channels: a paradigm for childhood absence epilepsy mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17156077" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Common polymorphisms in the CACNA1H gene associated with childhood absence epilepsy in Chinese Han population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16905256" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : New variants in the CACNA1H gene identified in childhood absence epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12891677" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Association between genetic variation of CACNA1H and childhood absence epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17580110" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Linkage and mutational analysis of CLCN2 in childhood absence epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12612585" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Mutations in CLCN2 encoding a voltage-gated chloride channel are associated with idiopathic generalized epilepsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12117362" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : A splice-site mutation in GABRG2 associated with childhood absence epilepsy and febrile convulsions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16939858" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : CACNA1I is not associated with childhood absence epilepsy in the Chinese Han population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12676336" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : T-type calcium channel gene alpha (1G) is not associated with childhood absence epilepsy in the Chinese Han population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16504478" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Evaluation of CACNA1H in European patients with childhood absence epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23280796" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Glucose transporter 1 deficiency in the idiopathic generalized epilepsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19798636" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Early-onset absence epilepsy caused by mutations in the glucose transporter GLUT1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23306390" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The role of SLC2A1 in early onset and childhood absence epilepsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21366555" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Refractory absence epilepsy associated with GLUT-1 deficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20574033" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Absence epilepsies with widely variable onset are a key feature of familial GLUT1 deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23020086" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Early-onset absence epilepsy: SLC2A1 gene analysis and treatment evolution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32437558" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Clinical and experimental insight into pathophysiology, comorbidity and therapy of absence seizures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21093357" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Spike-wave discharges in WAG/Rij rats are preceded by delta and theta precursor activity in cortex and thalamus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21675598" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : On the origin and suddenness of absences in genetic absence models.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23764296" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Focal corticothalamic sources during generalized absence seizures: a MEG study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28216336" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Pathophysiology of absence epilepsy: Insights from genetic models.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20608963" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Simultaneous EEG, fMRI, and behavior in typical childhood absence seizures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20427649" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Dynamic time course of typical childhood absence seizures: EEG, behavior, and functional magnetic resonance imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23586661" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Absence epilepsy subnetworks revealed by event-related independent components analysis of functional magnetic resonance imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23586661" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Absence epilepsy subnetworks revealed by event-related independent components analysis of functional magnetic resonance imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11051121" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : How well can epilepsy syndromes be identified at diagnosis? A reassessment 2 years after initial diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10219269" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Classification of childhood epilepsy syndromes in newly diagnosed epilepsy: interrater agreement and reasons for disagreement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3144826" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Epidemiology of absence epilepsy. I. Concept and incidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2369875" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Survey of seizure disorders in the French southwest. I. Incidence of epileptic syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2369875" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Survey of seizure disorders in the French southwest. I. Incidence of epileptic syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16638642" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : A population based study of epilepsy in children from a Swedish county.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16894100" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Electroclinical features of absence seizures in childhood absence epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8857718" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Long-term prognosis of typical childhood absence epilepsy: remission or progression to juvenile myoclonic epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28724582" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Pretreatment seizure semiology in childhood absence epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19124226" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Long-term outcome of childhood absence epilepsy: Dutch Study of Epilepsy in Childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26311751" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Long-term outcomes of generalized tonic-clonic seizures in a childhood absence epilepsy trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18557780" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Childhood absence epilepsy: behavioral, cognitive, and linguistic comorbidities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17947336" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : The frequency, complications and aetiology of ADHD in new onset paediatric epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30408705" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : The cognitive phenotype of idiopathic generalized epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23219245" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : The neuropsychological and academic substrate of new/recent-onset epilepsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20656561" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Dysfunction of executive and related processes in childhood absence epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18070088" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Global cognitive function in children with epilepsy: a community-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18675938" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Residual cognitive effects of uncomplicated idiopathic and cryptogenic epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16225738" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Special education needs of children with newly diagnosed epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37981446" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Childhood Absence Epilepsy- Electroclinical Profile and Prevalence of Attention-Deficit/Hyperactivity Disorder Among a Cohort of 47 Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23537619" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Attention impairment in childhood absence epilepsy: an impulsivity problem?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24089388" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Pretreatment cognitive deficits and treatment effects on attention in childhood absence epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23719147" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Pretreatment EEG in childhood absence epilepsy: associations with attention and treatment outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33751566" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Absence seizures and their relationship to depression and anxiety: Evidence for bidirectionality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30734897" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : A Practical Guide to Treatment of Childhood Absence Epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23167925" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29288644" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Out of thin air: Hyperventilation-triggered seizures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21282069" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Interictal paroxysmal EEG abnormalities in childhood absence epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19243419" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : EEG features of absence seizures in idiopathic generalized epilepsy: impact of syndrome, age, and state.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15158699" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : EEG in childhood absence epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11764182" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Frontal absences in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16499767" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Thalamic atrophy in childhood absence epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19624714" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Frontal and temporal volumes in Childhood Absence Epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19766541" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Amygdala volumes in childhood absence epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33029962" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Altered Structural Network in Newly Onset Childhood Absence Epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33029962" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Altered Structural Network in Newly Onset Childhood Absence Epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26537434" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : The role of SLC2A1 mutations in myoclonic astatic epilepsy and absence epilepsy, and the estimated frequency of GLUT1 deficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22282645" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : GLUT1 mutations are a rare cause of familial idiopathic generalized epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21962875" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Glut1 deficiency: when to suspect and how to diagnose?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24789115" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Long-term clinical course of Glut1 deficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25110966" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Triheptanoin for glucose transporter type I deficiency (G1D): modulation of human ictogenesis, cerebral metabolic rate, and cognitive indices by a food supplement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26536893" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34167046" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Epilepsy With Eyelid Myoclonia (Jeavons Syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35503717" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: Position paper by the ILAE Task Force on Nosology and Definitions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33475151" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29898971" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20200383" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12160672" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Topiramate monotherapy for childhood absence seizures: an open label pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15847848" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Zonisamide for absence seizures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23350722" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27986874" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Second monotherapy in childhood absence epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20647578" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Do patients with absence epilepsy respond to ketogenic diets?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22310062" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Efficacy of the ketogenic diet: which epilepsies respond?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23391567" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Vagus nerve stimulation for medically refractory absence epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37611408" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Efficacy and Tolerability of Ultra Rapid Duty Cycling Vagus Nerve Stimulation for Medically Refractory Absence Seizures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18808424" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Levetiracetam in absence epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21680209" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Aggravation of absence seizure related to levetiracetam.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30458657" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Clinical Use and Efficacy of Levetiracetam for Absence Epilepsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17666074" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Idiopathic generalized epilepsy with absences: syndrome classification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30856420" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Historical trend toward improved long-term outcome in childhood absence epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26239083" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Refractory absence seizures: An Italian multicenter retrospective study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
